Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 17:44:02 16/01/2025 GMT			5-day change	1st Jan Change
91.94 ^USD	-0.47%		+2.54%	-0.23%

01-15	Gilead Sciences, US government settle patent case over HIV prevention drugs	RE
01-13	Gilead to Seek M&A	CI

Raymond James Adjusts Gilead Sciences Price Target to $103 From $95, Maintains Outperform Rating

November 07, 2024 at 06:30 pm

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Gilead Sciences, Inc.

Gilead Sciences, US government settle patent case over HIV prevention drugs	01-15	RE
Gilead to Seek M&A	01-13	CI
Gilead Sciences, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 11:15 AM	01-13
Global markets live: Apple, Johnson & Johnson, Meta, Amazon, The Hershey, Eli Lilly...	01-13
Gilead Sciences Partners With LEO Pharma on Inflammatory Disease Therapies	01-13	MT
Gilead Sciences, Inc. and LEO Pharma Enter into Strategic Partnership to Accelerate Development of Oral STAT6 Program with Potential in Multiple Inflammatory Diseases	01-13	CI
Gilead, LEO Pharma partner to develop programs for inflammatory diseases	01-11	RE
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $125 From $123, Keeps Buy Rating	01-10	MT
Poolbeg Pharma notes Gilead interest in Hookipa fundraise	01-10	AN
Hiring highs trigger Wall Street woes: No cuts on the horizon	01-10
Morgan Stanley Upgrades Gilead Sciences to Overweight From Equalweight, Raises Price Target to $113 From $87	01-10	MT
Morgan Stanley Upgrades Gilead Sciences to Overweight From Equalweight, Adjusts Price Target to $113 From $87	01-10	MT
Analyst recommendations: AMD, McDonald's, Nike, Ross Stores, Snowflake...	01-10
Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%	01-08	MT
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors	01-08	CI
Galapagos's Spin-Off, the New Entity Will Apply to List on Euronext	01-08	CI
Netherland's Galapagos to spin off innovative medicines business	01-08	RE
Poolbeg and Hookipa deal gets support from major stakeholder	01-07	AN
RBC Trims Price Target on Gilead Sciences to $83 From $84, Keeps Sector Perform Rating	01-07	MT
Hookipa Shareholder Gilead Sciences to Back Poolbeg Merger	01-07	MT
Poolbeg in early stage talks to combine with US biotech, Hookipa	01-02	AN
Assembly Biosciences Says Antiviral Drug Shows 'Encouraging' Phase 1 Results	12-26	MT
Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding	12-19	DJ
Assembly Biosciences Says It Will Receive $30.1 Million Funding From Gilead Sciences	12-19	MT
Assembly Biosciences Gets $30.1 Million Equity Investment, Funding From Gilead	12-19	DJ

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Employees

18,000

Sector

Pharmaceuticals

Calendar

11/02/2025 - Q4 2024 Earnings Release

More about the company